Detalhe da pesquisa
1.
Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
CA Cancer J Clin
; 69(4): 280-304, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31099893
2.
Disparities in clinical trial enrollment at a Canadian comprehensive cancer center: A 15-year retrospective study.
Cancer
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662430
3.
High grade adverse event reporting and enrolment in gynecologic oncology clinical trials.
Gynecol Oncol
; 185: 1-7, 2024 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342004
4.
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Gynecol Oncol
; 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38834399
5.
Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancers.
Int J Gynecol Cancer
; 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38821545
6.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer
; 128(2): 255-265, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482193
7.
Emerging peptide therapeutics for the treatment of ovarian cancer.
Expert Opin Emerg Drugs
; 28(2): 129-144, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37282529
8.
Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study.
Support Care Cancer
; 31(7): 404, 2023 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37341839
9.
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Int J Gynecol Cancer
; 33(8): 1208-1214, 2023 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37380217
10.
Management of Malignant Bowel Obstruction: An Innovative Proactive Outpatient Nurse-Led Model of Care for Patients With Advanced Gynecologic Cancer.
J Nurs Care Qual
; 38(1): 69-75, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36214674
11.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(4): 465-478, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35298906
12.
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Lancet Oncol
; 23(8): e374-e384, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35901833
13.
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
; 397(10271): 281-292, 2021 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33485453
14.
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.
Gynecol Oncol
; 167(2): 226-233, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36055813
15.
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Gynecol Oncol
; 166(2): 254-262, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35718565
16.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273926
17.
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma.
Int J Gynecol Cancer
; 32(1): 89-92, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716177
18.
Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers.
Int J Gynecol Cancer
; 32(7): 891-898, 2022 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35012974
19.
Interobserver and intraobserver variability of RECIST assessment in ovarian cancer.
Int J Gynecol Cancer
; 32(5): 656-661, 2022 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35379690
20.
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Int J Gynecol Cancer
; 32(6): 761-768, 2022 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086926